Tsao et al. [32] initially reported that co-administration of 5-Aza and ABT-737 (inhibitor of BCL-2 and Bcl-xL) could increase mitochondrial outer membrane permeability among AML cells. Here, BCL2L1 is linked to acute myeloid leukemia.